Journal ArticleDOI
Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial.
Gilles Salles,John F. Seymour,Fritz Offner,Armando López-Guillermo,David Belada,Luc Xerri,Pierre Feugier,Reda Bouabdallah,John Catalano,Pauline Brice,Dolores Caballero,Corinne Haioun,Lars Moller Pedersen,Alain Delmer,David Simpson,Sirpa Leppä,Pierre Soubeyran,Anton Hagenbeek,Olivier Casasnovas,Tanin Intragumtornchai,Christophe Fermé,Maria Gomes da Silva,Catherine Sebban,Andrew Lister,Jane Estell,Gustavo Milone,Anne Sonet,Myriam Mendila,Bertrand Coiffier,Hervé Tilly +29 more
Reads0
Chats0
TLDR
2 years of rituximab maintenance therapy after immunochemotherapy as first-line treatment for follicular lymphoma significantly improves PFS.About:
This article is published in The Lancet.The article was published on 2011-01-01. It has received 947 citations till now. The article focuses on the topics: Rituximab & Follicular lymphoma.read more
Citations
More filters
Journal ArticleDOI
Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial
Mathias J. Rummel,Norbert Niederle,Georg Maschmeyer,G.-Andre Banat,Ulrich von Grünhagen,Christoph Losem,Dorothea Kofahl-Krause,Gerhard Heil,Manfred Welslau,Christina Balser,Ulrich Kaiser,Eckhart Weidmann,Heinz Dürk,Harald Ballo,Martina Stauch,Fritz Roller,Juergen Barth,Dieter Hoelzer,Axel Hinke,Wolfram Brugger +19 more
TL;DR: In patients with previously untreated indolent lymphoma, bendamustine plus rituximab can be considered as a preferred first-line treatment approach to R-CHOP because of increased progression-free survival and fewer toxic effects.
Journal ArticleDOI
Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
TL;DR: This work presents a meta-analysis of 120 cases of central giant cell granuloma in mice over a 12-month period and shows clear trends in survival and morbidity during the first year of treatment with chemotherapy.
Journal ArticleDOI
Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study
Carla Casulo,Michelle Byrtek,Keith L Dawson,Xiaolei Zhou,Charles M. Farber,Christopher R. Flowers,John D. Hainsworth,Matthew J. Maurer,James R. Cerhan,Brian K. Link,Andrew D. Zelenetz,Jonathan W. Friedberg,Jonathan W. Friedberg +12 more
TL;DR: In patients with FL who received first-line R-CHOP, POD within 2 years after diagnosis was associated with poor outcomes and should be further validated as a standard end point of chemoimmunotherapy trials of untreated FL.
Федеральное государственное бюджетное учреждение «Научно-исследовательский институт комплексных проблем сердечно-сосудистых заболеваний» Сибирского отделения Российской академии медицинских наук, Кемерово, Россия
S. V. Ivanov,A. N. Sumin,Y. V. Kazachek,D. E. Philipiev,S. M. Gusev,E. S. Malyshenko,L. S. Barbarash +6 more
TL;DR: The outcomes of CAD surgical treatment were improved in this group of patients due to the implementation of a mul-assisted revascularization of coronary and non-coronary arteries.
Journal ArticleDOI
Obinutuzumab for the First-Line Treatment of Follicular Lymphoma
Robert Marcus,Andrew Davies,Kiyoshi Ando,W. Klapper,Stephen Opat,Carolyn Owen,Elizabeth H Phillips,Randeep Sangha,Rudolf Schlag,John F. Seymour,William Townsend,Marek Trněný,Michael Wenger,Günter Fingerle-Rowson,Kaspar Rufibach,Tom Moore,Michael Herold,Wolfgang Hiddemann +17 more
TL;DR: Obinutuzumab‐based immunochemotherapy and maintenance therapy resulted in longer progression‐free survival than rituximab‐ based therapy.
References
More filters
Journal ArticleDOI
Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas
Bruce D. Cheson,Sandra J. Horning,B Coiffier,Margaret A. Shipp,Richard I. Fisher,J Connors,T A Lister,Julie M. Vose,Antonio J. Grillo-Lopez,A Hagenbeek,F Cabanillas,D Klippensten,W Hiddemann,R A Castellino,Nancy L. Harris,James O. Armitage,W. D. Carter,Richard T. Hoppe,George P. Canellos +18 more
TL;DR: Standardized guidelines for response assessment are needed to ensure comparability among clinical trials in non-Hodgkin's lymphomas (NHL), and two meetings were convened among United States and international lymphoma experts to develop a uniform set of criteria for assessing response in clinical trials.
Journal ArticleDOI
Follicular lymphoma international prognostic index.
Philippe Solal-Celigny,Pascal Roy,Philippe Colombat,J. M. White,James Olen Armitage,Reyes Arranz-Saez,Wing Yan Au,Monica Bellei,Pauline Brice,Dolores Caballero,Bertrand Coiffier,Eulogio Conde-Garcia,Chantal Doyen,Massimo Federico,Richard I. Fisher,Javier García-Conde,Cesare Guglielmi,Anton Hagenbeek,Corinne Haioun,Michael LeBlanc,Andrew Lister,Armando López-Guillermo,Peter McLaughlin,Noel Milpied,Pierre Morel,Nicolas Mounier,Stephen J. Proctor,Ama Z. S. Rohatiner,Paul Smith,Pierre Soubeyran,Hervé Tilly,Umberto Vitolo,Pier Luigi Zinzani,Emanuele Zucca,Emili Montserrat +34 more
TL;DR: The Follicular Lymphoma International Prognostic Index was designed from the data recorded over 8 years of nearly 5000 patients registered worldwide to help provide an optimal treatment option for patients with follicular lymphoma.
Journal ArticleDOI
Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group
Wolfgang Hiddemann,Michael Kneba,Martin Dreyling,Norbert Schmitz,Eva Lengfelder,Rudolf Schmits,Marcel Reiser,Bernd Metzner,Harriet Harder,Susanna Hegewisch-Becker,Thomas M. Fischer,Martin Kropff,Hans-Edgar Reis,Mathias Freund,Bernhard Wörmann,Roland Fuchs,Manfred Planker,Jörg Schimke,Hartmut Eimermacher,Lorenz Trümper,Ali Aldaoud,Reza Parwaresch,Michael Unterhalt +22 more
TL;DR: Adding rituximab to CHOP significantly improves the outcome for patients with previously untreated advanced-stage FL and does not induce major adverse effects.
Journal ArticleDOI
CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma
Robert Marcus,Kevin Imrie,Andrew R. Belch,David Cunningham,Eduardo Flores,John Catalano,Philippe Solal-Celigny,Fritz Offner,Jan Walewski,João Raposo,Andrew Jack,Paul Smith +11 more
TL;DR: The addition of rituximab to the CVP regimen significantly improves the clinical outcome in patients with previously untreated advanced follicular lymphoma, without increased toxicity.
Journal ArticleDOI
Follicular Lymphoma International Prognostic Index.
TL;DR: The Follicular Lymphoma International Prognostic Index was designed from the data recorded over 8 years of nearly 5000 patients registered worldwide to help provide an optimal treatment option for patients with follicular lymphoma.
Related Papers (5)
Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group
Wolfgang Hiddemann,Michael Kneba,Martin Dreyling,Norbert Schmitz,Eva Lengfelder,Rudolf Schmits,Marcel Reiser,Bernd Metzner,Harriet Harder,Susanna Hegewisch-Becker,Thomas M. Fischer,Martin Kropff,Hans-Edgar Reis,Mathias Freund,Bernhard Wörmann,Roland Fuchs,Manfred Planker,Jörg Schimke,Hartmut Eimermacher,Lorenz Trümper,Ali Aldaoud,Reza Parwaresch,Michael Unterhalt +22 more
Follicular lymphoma international prognostic index.
Philippe Solal-Celigny,Pascal Roy,Philippe Colombat,J. M. White,James Olen Armitage,Reyes Arranz-Saez,Wing Yan Au,Monica Bellei,Pauline Brice,Dolores Caballero,Bertrand Coiffier,Eulogio Conde-Garcia,Chantal Doyen,Massimo Federico,Richard I. Fisher,Javier García-Conde,Cesare Guglielmi,Anton Hagenbeek,Corinne Haioun,Michael LeBlanc,Andrew Lister,Armando López-Guillermo,Peter McLaughlin,Noel Milpied,Pierre Morel,Nicolas Mounier,Stephen J. Proctor,Ama Z. S. Rohatiner,Paul Smith,Pierre Soubeyran,Hervé Tilly,Umberto Vitolo,Pier Luigi Zinzani,Emanuele Zucca,Emili Montserrat +34 more
Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial
Mathias J. Rummel,Norbert Niederle,Georg Maschmeyer,G.-Andre Banat,Ulrich von Grünhagen,Christoph Losem,Dorothea Kofahl-Krause,Gerhard Heil,Manfred Welslau,Christina Balser,Ulrich Kaiser,Eckhart Weidmann,Heinz Dürk,Harald Ballo,Martina Stauch,Fritz Roller,Juergen Barth,Dieter Hoelzer,Axel Hinke,Wolfram Brugger +19 more
Follicular Lymphoma International Prognostic Index 2: A New Prognostic Index for Follicular Lymphoma Developed by the International Follicular Lymphoma Prognostic Factor Project
Massimo Federico,Monica Bellei,Luigi Marcheselli,Stefano Luminari,Armando López-Guillermo,Umberto Vitolo,Barbara Pro,Stefano Pileri,Alessandro Pulsoni,Pierre Soubeyran,Sergio Cortelazzo,Giovanni Martinelli,Maurizio Martelli,Luigi Rigacci,Luca Arcaini,Francesco Di Raimondo,Francesco Merli,Elena Sabattini,Peter McLaughlin,Philippe Solal-Celigny +19 more